Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | IDE | P14735 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 8/20 | 0.49 |
| ▸ | CA1 | P00915 | 8/20 | 0.49 |
| ▸ | CA2 | P00918 | 8/20 | 0.49 |
| ▸ | CA9 | Q16790 | 8/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.48 |
| ▸ | PTPRF | P10586 | 2/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.46 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31215417 | 0.89 | TDP1 (0.48) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL1772652 | 0.87 | TDP1 (0.49) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL1774374 | 0.85 | TDP1 (0.49) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL6734256 | 0.83 | TDP1 (0.62) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL20495575 | 0.83 | TDP1 (0.62) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL15067661 | 0.83 | TDP1 (0.62) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL29349497 | 0.83 | TDP1 (0.53) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL5808600 | 0.82 | TDP1 (0.57) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL4624128 | 0.82 | TDP1 (0.65) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL31378143 | 0.82 | TDP1 (0.68) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340591-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | ANYGEN CO LTD (KR) | 2025-11-06 | — | — | US | claimed |
| CN-117616034-A | Composition for preventing or treating inflammatory bowel disease containing novel compounds | 安尼根有限公司 | 2024-02-27 | — | — | CN | claimed |
| EP-4317171-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | Anygen Co., Ltd. (KR) | 2024-02-07 | — | — | EP | claimed |
| US-20230212222-A1 | COMPOSITION FOR ANTI-DIABETES AND ANTI-OBESITY COMPRISING NOVEL COMPOUND | ANYGEN CO., LTD. (KR) | 2023-07-06 | — | — | US | claimed |
| WO-2023038464-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | 애니젠 주식회사 | 2023-03-16 | — | — | WO | claimed |
| EP-4119570-A1 | COMPOSITION FOR ANTI-DIABETES AND ANTI-OBESITY COMPRISING NOVEL COMPOUND | Anygen Co., Ltd. (KR) | 2023-01-18 | — | — | EP | claimed |
| CN-115362165-A | Antidiabetic and antiobesity composition comprising novel compounds | 安尼根有限公司 | 2022-11-18 | — | — | CN | claimed |
| US-20250340591-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | ANYGEN CO LTD (KR) | 2025-11-06 | — | — | US | disclosed |
| US-20250313632-A1 | ANTI-B7-H3 ANTIBODIES AND USES THEREOF | Lepu Biopharma Co., Ltd. (CN) | 2025-10-09 | — | — | US | disclosed |
| CN-119451988-B | Anti-B7-H3 antibodies and uses thereof | 乐普创一生物科技（上海）有限公司 | 2025-06-03 | — | — | CN | disclosed |
| EP-4514853-A1 | ANTI-B7-H3 ANTIBODIES AND USES THEREOF | Concept to Medicine Biotech Co., Ltd. (CN) | 2025-03-05 | — | — | EP | disclosed |
| CN-119470877-A | Biotinylation modified amino acid probe, preparation method and application thereof, and method and application for identifying amino acid binding protein | 同济大学 | 2025-02-18 | — | — | CN | disclosed |
| CN-119432799-A | Method for preparing and purifying mRNA | 国际遗传工程和生物技术中心泰州区域研究中心 | 2025-02-14 | — | — | CN | disclosed |
| CN-117616034-A | Composition for preventing or treating inflammatory bowel disease containing novel compounds | 安尼根有限公司 | 2024-02-27 | — | — | CN | disclosed |
| EP-4317171-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | Anygen Co., Ltd. (KR) | 2024-02-07 | — | — | EP | disclosed |
| WO-2023208034-A1 | ANTI-B7-H3 ANTIBODIES AND USES THEREOF | CONCEPT TO MEDICINE BIOTECH CO., LTD. (CN) | 2023-11-02 | — | — | WO | disclosed |
| US-20230212222-A1 | COMPOSITION FOR ANTI-DIABETES AND ANTI-OBESITY COMPRISING NOVEL COMPOUND | ANYGEN CO., LTD. (KR) | 2023-07-06 | — | — | US | disclosed |
| WO-2023038464-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | 애니젠 주식회사 | 2023-03-16 | — | — | WO | disclosed |
| EP-4119570-A1 | COMPOSITION FOR ANTI-DIABETES AND ANTI-OBESITY COMPRISING NOVEL COMPOUND | Anygen Co., Ltd. (KR) | 2023-01-18 | — | — | EP | disclosed |
| CN-115362165-A | Antidiabetic and antiobesity composition comprising novel compounds | 安尼根有限公司 | 2022-11-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340591-A1 | COMPOSITION FOR PREVENTING OR TREATING INFLAMMATORY BOWEL DISEASE CONTAINING NOVEL COMPOUND | GPR39, FABP2, GPR119 | TDP1 4831/4885MEN1 4772/4885ABL1 4137/4885 |
| US-20230212222-A1 | COMPOSITION FOR ANTI-DIABETES AND ANTI-OBESITY COMPRISING NOVEL COMPOUND | GPR119, GPR39, FABP4 | TDP1 4730/4885MEN1 4708/4885ABL1 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.